LMT503 First-in-human SAD, MAD, and FE Study

Summary

This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and PK of ascending single and multiple oral doses of LMT503. The study will start with the SAD part.

Timeline

Start

2025-04-01

Primary completion

2025-10-01

Completion

2026-03-01

Drugs

Indications